Evidence map›Paper›PMID 34600567›Full record

ReviewOrphanet journal of rare diseases2021

Fondazione Telethon and Unione Italiana Lotta alla Distrofia Muscolare, a successful partnership for neuromuscular healthcare research of value for patients.

Anna Ambrosini, Danila Baldessari, Silvia Pozzi, Manuela Battaglia, Elena Beltrami, Anna Maria Merico, Marco Rasconi, Lucia Monaco

Open access · goldAbstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Anna AmbrosiniFondazione Telethon, Via Poerio 14, Milan, Italy. aambrosini@telethon.it.ORCID 0000-0002-3065-975X
Danila BaldessariFondazione Telethon, Via Poerio 14, Milan, Italy.
Silvia PozziFondazione Telethon, Via Poerio 14, Milan, Italy.
Manuela BattagliaFondazione Telethon, Via Poerio 14, Milan, Italy.
Elena BeltramiFondazione Telethon, Via Poerio 14, Milan, Italy.
Anna Maria MericoFondazione Telethon, Via Poerio 14, Milan, Italy.
Marco RasconiUILDM, Unione Italiana Lotta alla Distrofia Muscolare, Padua, Italy.
Lucia MonacoFondazione Telethon, Via Poerio 14, Milan, Italy.
Telethon Foundation · ITFIT Consulting (Italy) · ITUnione Italiana del Lavoro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2001, Fondazione Telethon and the Italian muscular dystrophy patient organisation Unione Italiana Lotta alla Distrofia Muscolare joined their efforts to design and launch a call for grant applications specifically dedicated to clinical projects in the field of neuromuscular disorders. This strategic initiative, run regularly over the years and still ongoing, aims at supporting research with impact on the daily life of people with a neuromuscular condition and is centred on macro-priorities identified by the patient organisation. It is investigator-driven, and all proposals are peer-reviewed for quality and feasibility. Over the years, this funding program contributed to strengthening the activities of the Italian neuromuscular clinical network, reaching many achievements in healthcare research. Moreover, it has been an enabling factor for innovative therapy experimentation at international level and prepared the clinical ground to make therapies available to Italian patients. The ultimate scope of healthcare research is to ameliorate the delivery of care. In this paper, the achievements of the funded studies are analysed also from this viewpoint, to ascertain to which extent they have fulfilled the original goals established by the patient organisation. The evidence presented indicates that this has been a highly fruitful program. Factors that contributed to its success, lessons learned, challenges, and issues that remain to be addressed are discussed to provide practical examples of an experience that could inspire also other organizations active in the field of rare disease research.

Indexed as

Muscular DystrophiesNeuromuscular DiseasesHealth Services ResearchHumansItalyRare DiseasesHealthcare researchInnovative therapiesNeuromuscular disordersPatient empowermentTrial readiness

Identifiers

PMID34600567
PMCPMC8487484
OpenAlexW3203065787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.